Verve Therapeutics Inc (VERV) Actualités

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class...

Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 31...

Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference

BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class...

Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones

Initial data for the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in second quarter of...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class...

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class...

Form 4 - Statement of changes in beneficial ownership of securities

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report